Latest Headline

April 4, 2024 - GlobeNewsWire

Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions

"This is an exciting improvement for the treatment of ischemic stroke due to large vessel occlusion. Higher recanalization rates on the first attempt are correlated with better outcomes for patients. This cyclic aspiration technology enabled fast and remarkable rates of excellent first pass recanalization rates. This may lead to reduced use of stent retrievers.” – Dr. Serdar Geyik

Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions

April 4, 2024 | Source: GlobeNewsWire

May 31, 2023

RapidPulse investors extend Series A funding with $10M

The company is gearing up for FDA submission in the fourth quarter of 2023

May 31, 2023

May 24, 2023

RapidPulse Feasibility Study Results Presented at European Stroke Organization Committee Annual Meeting

Data from five hospitals showed FPE TICI≥2c rate was 60% with RapidPulse...only 38.5% with standard aspiration

May 24, 2023 | ESOC 2023

September 13, 2022

RapidPulse, developer of a device for treating strokes, raises $10.5M

Its technology may double the success rate of quick clot removal leading to better patient outcomes

September 13, 2022 | Source: Steven Loeb, vatornews

September 13, 2022

RapidPulse Raises Funding for Ischemic Stroke Therapies

September 13, 2022 | Source: Endovascular Today

July 28, 2022

First human use cases results show RapidPulse enables doctors to get first pass effect results of TICI≥2c in 69% of cases…data presented at SNIS 2022

July 28, 2022 | Source: BMJ Journals

June 28, 2021

Stroke device maker RapidPulse spins out of Syntheon incubator

June 28, 2021 | Source: Andrea Park, FierceBiotech

June 23, 2021

RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy

Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke

June 23, 2021 | Source: GlobeNewswire

More Complete Reperfusion with the RapidPulse™ Aspiration System

Latest Headline

April 4, 2024 - GlobeNewsWire

Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions

The rate of FPE (mTICI ≥2c after one-pass) was significantly higher in the RapidPulse-cohort than in the historical cohort (69% [20/29] vs. 28%; p<0.0001).

Archives

Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions

RapidPulse investors extend Series A funding with $10M

The company is gearing up for FDA submission in the fourth quarter of 2023

RapidPulse Feasibility Study Results Presented at European Stroke Organization Committee Annual Meeting

Data from five hospitals showed FPE TICI≥2c rate was 60% with RapidPulse...only 38.5% with standard aspiration

RapidPulse, developer of a device for treating strokes, raises $10.5M

Its technology may double the success rate of quick clot removal leading to better patient outcomes

RapidPulse Raises Funding for Ischemic Stroke Therapies

First human use cases results show RapidPulse enables doctors to get first pass effect results of TICI≥2c in 69% of cases…data presented at SNIS 2022

Stroke device maker RapidPulse spins out of Syntheon incubator

RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy

Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke

More Complete Reperfusion with the RapidPulse™ Aspiration System

Latest Headline

April 4, 2024 - GlobeNewsWire

Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions

The rate of FPE (mTICI ≥2c after one-pass) was significantly higher in the RapidPulse-cohort than in the historical cohort (69% [20/29] vs. 28%; p<0.0001).

Archives

Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions

RapidPulse investors extend Series A funding with $10M

The company is gearing up for FDA submission in the fourth quarter of 2023

RapidPulse Feasibility Study Results Presented at European Stroke Organization Committee Annual Meeting

Data from five hospitals showed FPE TICI≥2c rate was 60% with RapidPulse...only 38.5% with standard aspiration

RapidPulse, developer of a device for treating strokes, raises $10.5M

Its technology may double the success rate of quick clot removal leading to better patient outcomes

RapidPulse Raises Funding for Ischemic Stroke Therapies

First human use cases results show RapidPulse enables doctors to get first pass effect results of TICI≥2c in 69% of cases…data presented at SNIS 2022

Stroke device maker RapidPulse spins out of Syntheon incubator

RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy

Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke

This website uses cookies.